|
NDFIP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.77129999948222E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.0954000000396E-06 |
| Normal-vs-Stage2 |
3.049200E-01 |
| Normal-vs-Stage3 |
1.0938999994714E-07 |
| Normal-vs-Stage4 |
3.73949999998846E-06 |
| Stage1-vs-Stage2 |
6.034000E-02 |
| Stage1-vs-Stage3 |
1.289440E-01 |
| Stage1-vs-Stage4 |
1.026620E-01 |
| Stage2-vs-Stage3 |
1.151660E-02 |
| Stage2-vs-Stage4 |
9.901700E-03 |
| Stage3-vs-Stage4 |
6.698400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.07819999595193E-08 |
| Normal-vs-AfricanAmerican |
6.341200E-01 |
| Normal-vs-Asian |
2.00659999999298E-05 |
| Caucasian-vs-AfricanAmerican |
7.397900E-02 |
| Caucasian-vs-Asian |
9.421200E-01 |
| AfricanAmerican-vs-Asian |
9.485600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.88180000000515E-05 |
| Normal-vs-Female |
3.41969999984038E-07 |
| Male-vs-Female |
8.335400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.94320000002079E-06 |
| Normal-vs-Age(41-60Yrs) |
1.5436799999935E-05 |
| Normal-vs-Age(61-80Yrs) |
2.07249999999437E-05 |
| Normal-vs-Age(81-100Yrs) |
1.645710E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.538000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.450200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.776800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.261000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.586200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.019200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.78870000003373E-06 |
| Classical-VS-Follicular |
9.20789999803162E-08 |
| Classical-VS-Other |
6.255400E-01 |
| Classical-VS-Normal |
4.85140000394679E-08 |
| Tall-VS-Follicular |
1.7732482149313E-12 |
| Tall-VS-Other |
3.078900E-03 |
| Tall-VS-Normal |
1.79856129989275E-14 |
| Follicular-VS-Other |
1.727370E-01 |
| Follicular-VS-Normal |
7.677400E-01 |
| Other-VS-Normal |
5.483500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.959500E-04 |
| Normal-vs-N1 |
6.37589999685773E-08 |
| N0-vs-N1 |
7.340000E-03 |
|
|
